WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000029578) CLONING AND CHARACTERIZATION OF TWO M-RNA TRANSCRIPTION FACTORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/029578    International Application No.:    PCT/US1999/026792
Publication Date: 25.05.2000 International Filing Date: 10.11.1999
Chapter 2 Demand Filed:    07.06.2000    
IPC:
A61K 38/00 (2006.01), A61K 48/00 (2006.01), C07K 14/47 (2006.01), C07K 16/18 (2006.01)
Applicants: THE GOVERNMENT OF THE UNITED STATES IF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; The National Institutes of Health Office of Technology Transfer Suite 325 6011 Executive Boulevard Rockville, MD 20852 (US) (For All Designated States Except US).
GE, Hui [CN/US]; (US) (For US Only)
Inventors: GE, Hui; (US)
Agent: NOONAN, William, D.; Klarquist, Sparkman, Campbell, Leigh & Whinston, LLP One World Trade Center, Suite 1600 121 SW Salmon Street Portland, OR 97204 (US)
Priority Data:
60/108,248 13.11.1998 US
Title (EN) CLONING AND CHARACTERIZATION OF TWO M-RNA TRANSCRIPTION FACTORS
(FR) CLONAGE ET CARACTÉRISATION DE DEUX FACTEURS DE TRANSCRIPTION DE L'ARN MESSAGER
Abstract: front page image
(EN)DNA and protein sequences are disclosed for coactivators of mRNA transcription identified as p52 and p75. The p52 sequence also enhances ASF/SF2-mediated pre-mRNA splicing activity. The disclosure also includes specific binding agents (such as antibodies) that recognize these activators, methods of enhancing transcription using the activators, methods of treating disease caused by mutations, therapeutic compositions that include the activators, recombinant DNA molecules, probes, and transformed cells that incorporate the DNA sequence to express p52 and p75. The disclosure also includes methods of diagnosis and treatment of diseases caused by an underexpression of p52 and/or p75, including tumors such as breast adenocarcinomas.
(FR)La présente invention concerne de l'ADN et des séquences de protéines destinées à des coactivateurs de la transcription de l'ARN messager et identifiées comme p52 et p75. La séquence p52 renforce également l'activité d'épissurage de l'ARN pré-messager à médiation d'ASF/SF2. L'invention concerne également des agents de liaison spécifiques tels que les anticorps, qui reconnaissent ces activateurs, des procédés permettant de renforcer la transcription par utilisation de ces activateurs, le traitement d'affection imputable à des mutations, des compositions incluant les activateurs, des molécules d'ADN recombinant, des sondes, et des cellules transformées incorporant la séquence d'ADN de façon à exprimer p52 et p75. L'invention concerne enfin le diagnostic et le traitement d'affections imputables à une sous-expression du p52 et/ou du p75, y compris des tumeurs telles que l'adénocarcinome du sein.
Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)